YS Biopharma Co Alpha and Beta Analysis
| YSDelisted Stock | 1.42 0.05 3.65% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as YS Biopharma Co. It also helps investors analyze the systematic and unsystematic risks associated with investing in YS Biopharma over a specified time horizon. Remember, high YS Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to YS Biopharma's market risk premium analysis include:
Beta (1.35) | Alpha 0.0261 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
YS Biopharma |
YS Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. YS Biopharma market risk premium is the additional return an investor will receive from holding YS Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in YS Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate YS Biopharma's performance over market.| α | 0.03 | β | -1.35 |
YS Biopharma Fundamentals Vs Peers
Comparing YS Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze YS Biopharma's direct or indirect competition across all of the common fundamentals between YS Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as YS Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of YS Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing YS Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare YS Biopharma to competition |
| Fundamentals | YS Biopharma | Peer Average |
| Return On Equity | -0.78 | -0.31 |
| Return On Asset | -0.1 | -0.14 |
| Profit Margin | (0.67) % | (1.27) % |
| Operating Margin | (0.49) % | (5.51) % |
| Current Valuation | 430.4 M | 16.62 B |
| Shares Outstanding | 188.33 M | 571.82 M |
| Shares Owned By Insiders | 81.42 % | 10.09 % |
YS Biopharma Opportunities
YS Biopharma Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About YS Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including YS Biopharma or other delisted stocks. Alpha measures the amount that position in YS Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
YS Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of YS Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, YS Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of YS Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of YS Biopharma. Please utilize our Beneish M Score to check the likelihood of YS Biopharma's management manipulating its earnings.
| 22nd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Build Portfolio with YS Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |